肾衰宁胶囊配合非奈利酮治疗糖尿病肾病临床研究  

Clinical Study of Shenshuaining Capsule Combined with Finerenone in the Treatment of Diabetic Nephropathy

作　　者：刘平 LIU Ping(Department of Endocrine Metabolism,Nanping Second Hospital,Nanping 354200,China)

机构地区：[1]南平市第二医院内分泌代谢科,福建南平354200

出　　处：《中西医结合研究》2025年第1期10-13,共4页Research of Integrated Traditional Chinese and Western Medicine

摘　　要：目的 观察肾衰宁胶囊配合非奈利酮对糖尿病肾病的治疗效果及对患者微炎症状态的影响。方法 将116例糖尿病肾病患者按数字抽签法随机为对照组和试验组,每组58例。在维持既往降糖方案基础上,对照组予以非奈利酮治疗,试验组予以肾衰宁胶囊配合非奈利酮治疗。比较2组治疗8周后的临床总有效率,肾功能指标[血清胱抑素C(cystatin C,Cys C)、尿素氮(blood urea nitrogen, BUN)、血肌酐(serum creatinine, Scr)],微炎症指标[白介素-1β(interleukin-1β,IL-1β)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、降钙素原(procalcitonin, PCT)]及不良反应发生率。结果 治疗8周后,试验组临床总有效率为93.10%,对照组为79.31%,试验组临床总有效率明显高于对照组(P<0.05)。2组血清Cys C、BUN、Scr水平均低于治疗前(P均<0.05),且试验组上述肾功能指标低于对照组(P均<0.05)。2组血清IL-1β、TNF-α、PCT水平均低于治疗前(P均<0.05),且试验组上述炎症指标低于对照组(P均<0.05)。试验组不良反应发生率为13.79%,对照组为10.34%,组间比较,差异无统计学意义(P>0.05)。结论 肾衰宁胶囊配合非奈利酮治疗糖尿病肾病可改善肾功能,减轻微炎症状态,疗效显著且安全性良好。Objective To observe the therapeutic effect of Shenshuaining capsule combined with finerenone on diabetic nephropathy and its effects on the micro-inflammatory state of patients.Methods A total of 116 patients with diabetic nephropathy were randomly divided into the control group and the trial group according to the number drawing method,with 58 cases in each group.On the basis of maintaining the previous hypoglycemic plan,the control group was treated with finerenone,while the trial group was treated with Shenshuaining capsule in combination with finerenone.The clinical total effective rate,renal function indicators[serum cystatin C(Cys C),blood urea nitrogen(BUN),serum creatinine(Scr)],micro inflammatory indicators[interleukin-1β(IL-1β),tumor necrosis factor-α(TNF-α),procalcitonin(PCT)],and incidence of adverse reactions in the two groups after 8 weeks of treatment were compared.Results After 8 weeks of treatment,the clinical total effective rate of the trial group was 93.10%,while that of the control group was 79.31%.The clinical total effective rate of the trial group was significantly higher than that of the control group(P<0.05).The serum levels of Cys C,BUN and Scr in both groups were lower than those before treatment(all P<0.05),and the above renal function indicators in the trial group were lower than those in the control group(all P<0.05).The serum levels of IL-1β,TNF-αand PCT in both groups were lower than those before treatment(all P<0.05),and the above inflammatory indicators in the trial group were lower than those in the control group(all P<0.05).The incidence of adverse reactions in the trial group was 13.79%,while the control group was 10.34%.There was no statistically significant difference between the two groups(P>0.05).Conclusion The combination of Shenshuaining capsule and finerenone in the treatment of diabetic nephropathy could improve renal function,reduce the state of micro-inflammation,which is with significant efficacy and good safety.

关 键 词：糖尿病肾病 非奈利酮 肾衰宁胶囊 微炎症状态 

分 类 号：R259[医药卫生—中西医结合]